Tuberculosis and HIV co-infection

PLoS Pathogens

Volumn 8, Issue 2, 2012, Pages

  Pawlowski, Andrzej ^a   Jansson, Marianne ^a,b   Sköld, Markus ^a   Rottenberg, Martin E ^a   Källenius, Gunilla ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; CD209 ANTIGEN; CELL PROTEIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DECOY RECEPTOR D6; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 27; NEUTRALIZING ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E2; RANTES; SMALL INTERFERING RNA; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN CONTAINING PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANIMAL; BACTERIAL CLEARANCE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOTAXIS; COMPLICATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; DISEASE EXACERBATION; DOWN REGULATION; EFFECTOR CELL; GRANULOMA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOLOGY; INFECTION RISK; LATENT TUBERCULOSIS; LONG TERMINAL REPEAT; LUNG ALVEOLUS MACROPHAGE; LYMPH NODE; MEMORY T LYMPHOCYTE; MIXED INFECTION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; TH1 TH2 BALANCE; TUBERCULOSIS; UPREGULATION; VIRAL TROPISM; VIRUS GENOME; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANIMALS; COINFECTION; COMPLICATIONS; HIV INFECTIONS; HUMANS; IMMUNOLOGY; TUBERCULOSIS;

ANIMALIA; MYCOBACTERIUM TUBERCULOSIS;

EID: 84860908291     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002464     Document Type: Review

References (119)

1. World Health Organization (2010) Global tuberculosis control 2010. Available: http://www.who.int/tb/publications/global_report/2010/en/index.html. Accessed 13 January 2012.
2. UNAIDS (2010) Chapter 2: epidemic update. UNAIDS report on the global AIDS epidemic 2010. Available: http://www.unaids.org/documents/20101123_GlobalReport_Chap2_em.pdf. Accessed 13 January 2012.
3. Getahun H, Gunneberg C, Granich R, Nunn P, (2010) HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 50 (Suppl 3): S201-S207.
4. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
5. Collins KR, Quinones-Mateu ME, Toossi Z, Arts EJ, (2002) Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev 4: 165-176.
6. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, et al. (1989) A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 320: 545-550.
7. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, et al. (1995) Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 151: 129-135.
8. Modjarrad K, Vermund SH, (2010) Effect of treating co-infections on HIV-1 viral load: a systematic review. Lancet Infect Dis 10: 455-463.
9. Moller M, Hoal EG, (2010) Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis. Tuberculosis (Edinb) 90: 71-83.
10. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, et al. (1997) Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A 94: 5243-5248.
11. Walker L, Lowrie DB, (1981) Killing of Mycobacterium microti by immunologically activated macrophages. Nature 293: 69-71.
12. MacMicking JD, Taylor GA, McKinney JD, (2003) Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 302: 654-659.
13. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM, (2002) Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 70: 4501-4509.
14. Cooper AM, (2009) T cells in mycobacterial infection and disease. Curr Opin Immunol 21: 378-384.
15. North RJ, Jung YJ, (2004) Immunity to tuberculosis. Annu Rev Immunol 22: 599-623.
16. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR, (1992) Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 89: 12013-12017.
17. Feng CG, Bean AG, Hooi H, Briscoe H, Britton WJ, (1999) Increase in gamma interferon-secreting CD8(+), as well as CD4(+), T cells in lungs following aerosol infection with Mycobacterium tuberculosis. Infect Immun 67: 3242-3247.
18. Ladel CH, Blum C, Dreher A, Reifenberg K, Kaufmann SH, (1995) Protective role of gamma/delta T cells and alpha/beta T cells in tuberculosis. Eur J Immunol 25: 2877-2881.
19. Lazarevic V, Flynn J, (2002) CD8+ T cells in tuberculosis. Am J Respir Crit Care Med 166: 1116-1121.
20. Orme IM, Roberts AD, Griffin JP, Abrams JS, (1993) Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J Immunol 151: 518-525.
21. Chan J, Flynn J, (2004) The immunological aspects of latency in tuberculosis. Clin Immunol 110: 2-12.
22. Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S, (2007) Should a new tuberculosis vaccine be administered intranasally? Tuberculosis (Edinb) 87: 257-266.
23. Hess C, Altfeld M, Thomas SY, Addo MM, Rosenberg ES, et al. (2004) HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet 363: 863-866.
24. Streeck H, Brumme ZL, Anastario M, Cohen KW, Jolin JS, et al. (2008) Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 5: e100 doi:10.1371/journal.pmed.0050100.
25. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, et al. (2010) Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 201: 1045-1053.
26. Brenchley JM, Douek DC, (2008) HIV infection and the gastrointestinal immune system. Mucosal Immunol 1: 23-30.
27. Moir S, Chun TW, Fauci AS, (2011) Pathogenic mechanisms of HIV disease. Annu Rev Pathol 6: 223-248.
28. Kanwar B, Favre D, McCune JM, (2010) Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr Opin HIV AIDS 5: 151-157.
29. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
30. Fitzgerald-Bocarsly P, Jacobs ES, (2010) Plasmacytoid dendritic cells in HIV infection: striking a delicate balance. J Leukoc Biol 87: 609-620.
31. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, et al. (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857-860.
32. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, et al. (2009) HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol 83: 2743-2755.
33. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, et al. (2010) Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 6: e1000917 doi:10.1371/journal.ppat.1000917.
34. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, et al. (2008) Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29: 1009-1021.
35. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
36. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, et al. (2008) Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205: 2763-2779.
37. Wang X, Cao Z, Jiang J, Li Y, Dong M, et al. (2011) Elevated expression of Tim-3 on CD8 T cells correlates with disease severity of pulmonary tuberculosis. J Infect 62: 292-300.
38. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC, (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282: 677-686.
39. Lillebaek T, Dirksen A, Vynnycky E, Baess I, Thomsen VO, et al. (2003) Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection. J Infect Dis 188: 1032-1039.
40. Aaron L, Saadoun D, Calatroni I, Launay O, Memain N, et al. (2004) Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 10: 388-398.
41. Lewinsohn DA, Winata E, Swarbrick GM, Tanner KE, Cook MS, et al. (2007) Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog 3: e127 doi:10.1371/journal.ppat.0030127.
42. Lewinsohn DA, Heinzel AS, Gardner JM, Zhu L, Alderson MR, et al. (2003) Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells. Am J Respir Crit Care Med 168: 1346-1352.
43. van Pinxteren LA, Ravn P, Agger EM, Pollock J, Andersen P, (2000) Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol 7: 155-160.
44. Chen CY, Huang D, Wang RC, Shen L, Zeng G, et al. (2009) A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog 5: e1000392 doi:10.1371/journal.ppat.1000392.
45. Rosas-Taraco AG, Arce-Mendoza AY, Caballero-Olin G, Salinas-Carmona MC, (2006) Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. AIDS Res Hum Retroviruses 22: 45-51.
46. Spear GT, Kessler HA, Rothberg L, Phair J, Landay AL, (1990) Decreased oxidative burst activity of monocytes from asymptomatic HIV-infected individuals. Clin Immunol Immunopathol 54: 184-191.
47. Wahl SM, Allen JB, Gartner S, Orenstein JM, Popovic M, et al. (1989) HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J Immunol 142: 3553-3559.
48. Havlir DV, Barnes PF, (1999) Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 340: 367-373.
49. Patel NR, Zhu J, Tachado SD, Zhang J, Wan Z, et al. (2007) HIV impairs TNF-alpha mediated macrophage apoptotic response to Mycobacterium tuberculosis. J Immunol 179: 6973-6980.
50. Roberts T, Beyers N, Aguirre A, Walzl G, (2007) Immunosuppression during active tuberculosis is characterized by decreased interferon - gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor-beta, and interleukin-4 mRNA levels. J Infect Dis 195: 870-878.
51. Pearl JE, Khader SA, Solache A, Gilmartin L, Ghilardi N, et al. (2004) IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice. J Immunol 173: 7490-7496.
52. Bonecini-Almeida MG, Ho JL, Boechat N, Huard RC, Chitale S, et al. (2004) Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis. Infect Immun 72: 2628-2634.
53. Carow B, Ye X, Gavier-Widen D, Bhuju S, Oehlmann W, et al. (2011) Silencing suppressor of cytokine signaling-1 (SOCS1) in macrophages improves Mycobacterium tuberculosis control in an interferon-gamma (IFN-gamma)-dependent manner. J Biol Chem 286: 26873-26887.
54. Hirsch CS, Hussain R, Toossi Z, Dawood G, Shahid F, et al. (1996) Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc Natl Acad Sci U S A 93: 3193-3198.
55. Di Liberto D, Locati M, Caccamo N, Vecchi A, Meraviglia S, et al. (2008) Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection. J Exp Med 205: 2075-2084.
56. Diedrich CR, Flynn JL, (2011) HIV-1/mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun 79: 1407-1417.
57. Sharma SK, Mohan A, Kadhiravan T, (2005) HIV-TB co-infection: epidemiology, diagnosis & management. Indian J Med Res 121: 550-567.
58. de Noronha AL, Bafica A, Nogueira L, Barral A, Barral-Netto M, (2008) Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production. Pathol Res Pract 204: 155-161.
59. Diedrich CR, Mattila JT, Klein E, Janssen C, Phuah J, et al. (2010) Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS ONE 5: e9611 doi:10.1371/journal.pone.0009611.
60. Mtei L, Matee M, Herfort O, Bakari M, Horsburgh CR, et al. (2005) High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 40: 1500-1507.
61. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr, (1993) Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 342: 268-272.
62. Nakata K, Rom WN, Honda Y, Condos R, Kanegasaki S, et al. (1997) Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 155: 996-1003.
63. Lawn SD, Pisell TL, Hirsch CS, Wu M, Butera ST, et al. (2001) Anatomically compartmentalized human immunodeficiency virus replication in HLA-DR+ cells and CD14+ macrophages at the site of pleural tuberculosis coinfection. J Infect Dis 184: 1127-1133.
64. Shattock RJ, Friedland JS, Griffin GE, (1993) Modulation of HIV transcription in and release from human monocytic cells following phagocytosis of Mycobacterium tuberculosis. Res Virol 144: 7-12.
65. Zhang Y, Nakata K, Weiden M, Rom WN, (1995) Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest 95: 2324-2331.
66. Toossi Z, Nicolacakis K, Xia L, Ferrari NA, Rich EA, (1997) Activation of latent HIV-1 by Mycobacterium tuberculosis and its purified protein derivative in alveolar macrophages from HIV-infected individuals in vitro. J Acquir Immune Defic Syndr Hum Retrovirol 15: 325-331.
67. Goletti D, Weissman D, Jackson RW, Collins F, Kinter A, et al. (1998) The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to Mycobacterium tuberculosis is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. J Infect Dis 177: 1332-1338.
68. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, et al. (1996) Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 157: 1271-1278.
69. Nakata K, Weiden M, Harkin T, Ho D, Rom WN, (1995) Low copy number and limited variability of proviral DNA in alveolar macrophages from HIV-1-infected patients: evidence for genetic differences in HIV-1 between lung and blood macrophage populations. Mol Med 1: 744-757.
70. Landay AL, Schade SZ, Takefman DM, Kuhns MC, McNamara AL, et al. (1993) Detection of HIV-1 provirus in bronchoalveolar lavage cells by polymerase chain reaction. J Acquir Immune Defic Syndr 6: 171-175.
71. Sierra-Madero JG, Toossi Z, Hom DL, Finegan CK, Hoenig E, et al. (1994) Relationship between load of virus in alveolar macrophages from human immunodeficiency virus type 1-infected persons, production of cytokines, and clinical status. J Infect Dis 169: 18-27.
72. Orenstein JM, Fox C, Wahl SM, (1997) Macrophages as a source of HIV during opportunistic infections. Science 276: 1857-1861.
73. Mancino G, Placido R, Bach S, Mariani F, Montesano C, et al. (1997) Infection of human monocytes with Mycobacterium tuberculosis enhances human immunodeficiency virus type 1 replication and transmission to T cells. J Infect Dis 175: 1531-1535.
74. Jiang W, Lederman MM, Salkowitz JR, Rodriguez B, Harding CV, et al. (2005) Impaired monocyte maturation in response to CpG oligodeoxynucleotide is related to viral RNA levels in human immunodeficiency virus disease and is at least partially mediated by deficiencies in alpha/beta interferon responsiveness and production. J Virol 79: 4109-4119.
75. Kedzierska K, Mak J, Mijch A, Cooke I, Rainbird M, et al. (2000) Granulocyte-macrophage colony-stimulating factor augments phagocytosis of Mycobacterium avium complex by human immunodeficiency virus type 1-infected monocytes/macrophages in vitro and in vivo. J Infect Dis 181: 390-394.
76. Biggs BA, Hewish M, Kent S, Hayes K, Crowe SM, (1995) HIV-1 infection of human macrophages impairs phagocytosis and killing of Toxoplasma gondii. J Immunol 154: 6132-6139.
77. Sacchi A, Cappelli G, Cairo C, Martino A, Sanarico N, et al. (2007) Differentiation of monocytes into CD1a-dendritic cells correlates with disease progression in HIV-infected patients. J Acquir Immune Defic Syndr 46: 519-528.
78. Muthumani K, Hwang DS, Choo AY, Mayilvahanan S, Dayes NS, et al. (2005) HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol 17: 103-116.
79. Ryo A, Tsurutani N, Ohba K, Kimura R, Komano J, et al. (2008) SOCS1 is an inducible host factor during HIV-1 infection and regulates the intracellular trafficking and stability of HIV-1 Gag. Proc Natl Acad Sci U S A 105: 294-299.
80. Fenner JE, Starr R, Cornish AL, Zhang JG, Metcalf D, et al. (2006) Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 7: 33-39.
81. Kedzierska K, Crowe SM, Turville S, Cunningham AL, (2003) The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Rev Med Virol 13: 39-56.
82. Jiao X, Lo-Man R, Guermonprez P, Fiette L, Deriaud E, et al. (2002) Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity. J Immunol 168: 1294-1301.
83. Donaghy H, Stebbing J, Patterson S, (2004) Antigen presentation and the role of dendritic cells in HIV. Curr Opin Infect Dis 17: 1-6.
84. van Kooyk Y, Appelmelk B, Geijtenbeek TB, (2003) A fatal attraction: Mycobacterium tuberculosis and HIV-1 target DC-SIGN to escape immune surveillance. Trends Mol Med 9: 153-159.
85. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, et al. (2000) DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100: 587-597.
86. Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR, (2002) DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 16: 135-144.
87. Geijtenbeek TB, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CM, et al. (2003) Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 197: 7-17.
88. Briken V, Porcelli SA, Besra GS, Kremer L, (2004) Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol Microbiol 53: 391-403.
89. Lawn SD, Bekker LG, Miller RF, (2005) Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 5: 361-373.
90. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, et al. (2010) Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 10: 251-261.
91. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, et al. (2008) Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 8: 516-523.
92. Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, et al. (2004) Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 39: 1709-1712.
93. Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, et al. (2006) Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 20: F1-7.
94. Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, et al. (2011) Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 203: 1637-1646.
95. Simonney N, Dewulf G, Herrmann JL, Gutierrez MC, Vicaut E, et al. (2008) Anti-PGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV-TB patients. Tuberculosis (Edinb) 88: 453-461.
96. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, et al. (2004) Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304: 104-107.
97. Gorantla S, Makarov E, Finke-Dwyer J, Gebhart CL, Domm W, et al. (2010) CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol 184: 7082-7091.
98. Denton PW, Krisko JF, Powell DA, Mathias M, Kwak YT, et al. (2010) Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS ONE 5: e8829 doi:10.1371/journal.pone.0008829.
99. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, et al. (2007) Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 204: 705-714.
100. Zhang L, Kovalev GI, Su L, (2007) HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 109: 2978-2981.
101. Baenziger S, Tussiwand R, Schlaepfer E, Mazzucchelli L, Heikenwalder M, et al. (2006) Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proc Natl Acad Sci U S A 103: 15951-15956.
102. Joseph A, Zheng JH, Chen K, Dutta M, Chen C, et al. (2010) Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol 84: 6645-6653.
103. Kumar P, Ban HS, Kim SS, Wu H, Pearson T, et al. (2008) T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134: 577-586.
104. Potash MJ, Chao W, Bentsman G, Paris N, Saini M, et al. (2005) A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc Natl Acad Sci U S A 102: 3760-3765.
105. Roshorm Y, Hong JP, Kobayashi N, McMichael AJ, Volsky DJ, et al. (2009) Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101(+) patients protected mice against chimaeric ecotropic HIV-1 challenge. Eur J Immunol 39: 1831-1840.
106. Saini M, Hadas E, Volsky DJ, Potash MJ, (2007) Vaccine-induced protection from infection of mice by chimeric human immunodeficiency virus type 1, EcoHIV/NL4-3. Vaccine 25: 8660-8663.
107. Hadas E, Borjabad A, Chao W, Saini M, Ichiyama K, et al. (2007) Testing antiretroviral drug efficacy in conventional mice infected with chimeric HIV-1. AIDS 21: 905-909.
108. Scanga CA, Bafica A, Sher A, (2007) Viral gene expression in HIV transgenic mice is activated by Mycobacterium tuberculosis and suppressed after antimycobacterial chemotherapy. J Infect Dis 195: 246-254.
109. Shen Y, Zhou D, Chalifoux L, Shen L, Simon M, et al. (2002) Induction of an AIDS virus-related tuberculosis-like disease in macaques: a model of simian immunodeficiency virus-mycobacterium coinfection. Infect Immun 70: 869-877.
110. Safi H, Gormus BJ, Didier PJ, Blanchard JL, Lakey DL, et al. (2003) Spectrum of manifestations of Mycobacterium tuberculosis infection in primates infected with SIV. AIDS Res Hum Retroviruses 19: 585-595.
111. Zhou D, Shen Y, Chalifoux L, Lee-Parritz D, Simon M, et al. (1999) Mycobacterium bovis bacille Calmette-Guerin enhances pathogenicity of simian immunodeficiency virus infection and accelerates progression to AIDS in macaques: a role of persistent T cell activation in AIDS pathogenesis. J Immunol 162: 2204-2216.
112. Shen Y, Shen L, Sehgal P, Huang D, Qiu L, et al. (2004) Clinical latency and reactivation of AIDS-related mycobacterial infections. J Virol 78: 14023-14032.
113. Kaufmann SH, McMichael AJ, (2005) Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 11: S33-S44.
114. Del Corno M, Liu QH, Schols D, de Clercq E, Gessani S, et al. (2001) HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin-insensitive chemokine receptor signaling. Blood 98: 2909-2916.
115. Portevin D, Gagneux S, Comas I, Young D, (2011) Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathog 7: e1001307 doi:10.1371/journal.ppat.1001307.
116. Locher CP, Witt SA, Kassel R, Dowell NL, Fujimura S, et al. (2005) Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation. J Gen Virol 86: 1171-1179.
117. Hiroi T, Goto H, Someya K, Yanagita M, Honda M, et al. (2001) HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J Immunol 167: 5862-5867.
118. Kawahara M, Hashimoto A, Toida I, Honda M, (2002) Oral recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. Clin Immunol 105: 326-331.
119. Yu JS, Peacock JW, Jacobs WR Jr, Frothingham R, Letvin NL, et al. (2007) Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. Clin Vaccine Immunol 14: 886-893.